SCHEMBL525420

SCHEMBL525420

O=C1CCCc2occ(-c3cccc(Cl)c3)c21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 3/20 0.43
ABL1 P00519 1/20 0.42
ABL2 P42684 1/20 0.42
ALOX15 P16050 1/20 0.42
ALOX12 P18054 1/20 0.42
PIK3CA P42336 1/20 0.42
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
KCNA3 P22001 1/20 0.40
CA12 O43570 2/20 0.39
CA9 Q16790 2/20 0.39
PARP10 Q53GL7 1/20 0.37
PARP11 Q9NR21 1/20 0.37
PGR P06401 1/20 0.37
SLC6A3 Q01959 1/20 0.36
SRC P12931 1/20 0.36
CHRNB4 P30926 1/20 0.36
CHRNA3 P32297 1/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL524971 0.87 ALDH1A1 (0.40) ALDH1A1SRCCYP1A2MAOAMAOB
SCHEMBL525198 0.83 MAPT (0.36) ALDH1A1KDM4EHPGDCHRNB4CHRNA3
SCHEMBL525511 0.83 CHRNB4 (0.36) ALDH1A1CHRNB4CHRNA3MAOAMAOB
SCHEMBL525548 0.83 KDM4E (0.38) KDM4EPARP10PARP11CHRNB4CHRNA3
SCHEMBL525732 0.83 ALOX15 (0.42) ALOX15ALOX12ALDH1A1KDM4EHPGD
SCHEMBL525638 0.82 BRD4 (0.43) ALOX15ALOX12PIK3CAALDH1A1KDM4E
SCHEMBL525730 0.82 SRC (0.43) PIK3CAALDH1A1HPGDPGRSLC6A3
SCHEMBL525555 0.80 BRD4 (0.52) ALDH1A1KDM4EHPGDKCNA3MIF
SCHEMBL525561 0.80 EGFR (0.38) EGFRABL1ABL2ALOX15ALOX12
SCHEMBL524806 0.80 TGFBR1 (0.34) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210290585-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH CORTICO-HIPPOCAMPAL HYPERACTIVITY UNIV RAMOT (IL) 2021-09-23 US claimed
EP-3544604-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH CORTICO-HIPPOCAMPAL HYPERACTIVITY Ramot at Tel-Aviv University Ltd. (IL) 2019-10-02 EP claimed
US-20190269644-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH CORTICO-HIPPOCAMPAL HYPERACTIVITY RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2019-09-05 US claimed
WO-2018096538-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH CORTICO-HIPPOCAMPAL HYPERACTIVITY RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2018-05-31 WO claimed
US-9315482-B2 Derivatives useful as antiviral agents INSTITUT PASTEUR (FR) 2016-04-19 US claimed
US-20130210886-A1 Novel Derivatives Useful as Antiviral Agents INSTITUT PASTEUR (FR) 2013-08-15 US claimed
EP-2598495-A1 NOVEL DERIVATIVES USEFUL AS ANTIVIRAL AGENTS Institut Pasteur (FR) 2013-06-05 EP claimed
EP-2420495-A1 Novel derivatives useful as antiviral agents Institut Pasteur (FR) 2012-02-22 EP claimed
WO-2012014181-A1 NOVEL DERIVATIVES USEFUL AS ANTIVIRAL AGENTS INSTITUT PASTEUR (FR) 2012-02-02 WO claimed
US-20240325760-A1 METHODS FOR DETECTING AND PREVENTING ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2024-10-03 US disclosed
EP-3864014-B1 MALONATE SALT OF VARLITINIB ASLAN PHARMACEUTICALS PTE LTD (SG) 2023-07-05 EP disclosed
US-20210379070-A1 MALONATE SALT OF VARLITINIB ASLAN PHARMACEUTICALS PTE LTD (SG) 2021-12-09 US disclosed
US-20210290585-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH CORTICO-HIPPOCAMPAL HYPERACTIVITY UNIV RAMOT (IL) 2021-09-23 US disclosed
US-11033524-B2 Methods and compositions for treating disorders associated with cortico-hippocampal hyperactivity RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2021-06-15 US disclosed
WO-2018096538-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH CORTICO-HIPPOCAMPAL HYPERACTIVITY RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2018-05-31 WO disclosed
US-9315482-B2 Derivatives useful as antiviral agents INSTITUT PASTEUR (FR) 2016-04-19 US disclosed
US-20130210886-A1 Novel Derivatives Useful as Antiviral Agents INSTITUT PASTEUR (FR) 2013-08-15 US disclosed
EP-2598495-A1 NOVEL DERIVATIVES USEFUL AS ANTIVIRAL AGENTS Institut Pasteur (FR) 2013-06-05 EP disclosed
EP-2420495-A1 Novel derivatives useful as antiviral agents Institut Pasteur (FR) 2012-02-22 EP disclosed
WO-2012014181-A1 NOVEL DERIVATIVES USEFUL AS ANTIVIRAL AGENTS INSTITUT PASTEUR (FR) 2012-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130210886-A1 Novel Derivatives Useful as Antiviral Agents MAVS, IRF3, IFNAR1 EGFR 3807/4885ABL1 1432/4885ABL2 4253/4885
US-20210379070-A1 MALONATE SALT OF VARLITINIB KRAS, JAK1, JAK2 EGFR 63/4885ABL1 20/4885ABL2 314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.